Pharmacogenetics of adverse effects due to antiretroviral drugs

AIDS Reviews

Volumn 12, Issue 1, 2010, Pages 15-30

  Vidal, Francesc ^a   Gutiérrez, Félix ^b   Gutiérrez, Mar ^c   Olona, Montserrat ^a   Sánchez, Victoria ^b   Mateo, Gracia ^c   Peraire, Joaquim ^a   Viladés, Consuelo ^a   Veloso, Sergi ^a   López Dupla, Miguel ^a   Domingo, Pere ^c  

^a HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Adverse effects; HAART; HIV; Pharmacogenetics

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; APOLIPOPROTEIN A5; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; HLA B27 ANTIGEN; INDINAVIR; INTERLEUKIN 1; INTERLEUKIN 6; LAMIVUDINE; MONOCYTE CHEMOTACTIC PROTEIN 1; NELFINAVIR; NEVIRAPINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEINASE INHIBITOR; RESISTIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; STROMAL CELL DERIVED FACTOR 1; TENOFOVIR; TUMOR NECROSIS FACTOR ALPHA; ZIDOVUDINE; HLA B ANTIGEN;

ACUTE PANCREATITIS; ACUTE TOXICITY; AGGRESSION; ATHEROSCLEROSIS; BODY FAT; CHRONIC TOXICITY; CLINICAL TRIAL; CONCENTRATION LOSS; DEPRESSION; DISEASE PREDISPOSITION; DIZZINESS; DNA POLYMORPHISM; DNA SEQUENCE; DROWSINESS; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG EXCRETION; DRUG FEVER; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DYSLIPIDEMIA; FAMILIAL PARTIAL LIPODYSTROPHY; FAMILY; GASTROINTESTINAL TOXICITY; GENE MUTATION; GENOTYPE; GLOMERULUS FILTRATION RATE; HAPLOTYPE; HEPATITIS; HEREDITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERAMYLASEMIA; HYPERBILIRUBINEMIA; HYPERLIPIDEMIA; HYPERSENSITIVITY REACTION; INSULIN RESISTANCE; JAUNDICE; KIDNEY DISEASE; KIDNEY INJURY; LABORATORY; LACTIC ACIDOSIS; LIPODYSTROPHY; LIPOLYSIS; LIVER DISEASE; LIVER INJURY; LIVER TOXICITY; LUNG TOXICITY; MANIA; MEDICAL RESEARCH; MENTAL INSTABILITY; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PARANOIA; PERIPHERAL NEUROPATHY; PHARMACOGENETICS; PSYCHOSIS; QUALITY OF LIFE; RASH; REVIEW; SCIENCE; SCREENING; SIDE EFFECT; SURVIVAL RATE; GENETIC VARIABILITY; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN GENOME; HUMAN IMMUNODEFICIENCY VIRUS; VIROLOGY;

ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL TRIALS AS TOPIC; GENETIC VARIATION; GENOME, HUMAN; HIV; HIV INFECTIONS; HLA-B ANTIGENS; HUMANS; PHARMACOGENETICS;

EID: 77953383326     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (166)

1. Gazzard B. Antiretroviral therapy for HIV: medical miracles do happen. Lancet. 2005;366:346-7.
2. Furrer H, Opravil M, Bernasconi E, Telenti A, Egger M. Stopping primary prophylaxis in HIV-1-infected patients at high risk of. Toxoplasma encephalitis. Swiss HIV Cohort Study. Lancet. 2000;355:2217-8.
3. López Bernaldo de Quirós J, Miró J, Peña J, et al. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98. N Engl J Med. 2001;344:159-67.
4. Martin A, Nolan D, Gaudieri S, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci USA. 2004;101:4180-5.
5. Berns J, Kasbekar N. Highly active antiretroviral therapy and the kidney: an update on antiretroviral medications for nephrologists. Clin J Am Soc Nephrol. 2006;1:117-29.
6. Núñez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol. 2006:44(Suppl 1):S132-9.
7. Mallon P. Pathogenesis of lipodystrophy and lipid abnormalities in patients taking antiretroviral therapy. AIDS Rev. 2007;9:3-15.
8. Oh J, Hegele R. HIV-associated dyslipidaemia: pathogenesis and treatment. Lancet Infect Dis. 2007;7:787-96.
9. Cressey T, Lallemant M. Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: An update. Infect Genet Evol. 2007;7:333-42.
10. Tarr P, Telenti A. Toxicogenetics of antiretroviral therapy: genetic factors that contribute to metabolic complications. Antivir Ther. 2007;12:999-1013.
11. The International HapMap Consortium. A haplotype map of the human genome. Nature. 2005;437:1299-320.
12. Hattersley A, McCarthy M. What makes a good genetic association study? Lancet. 2005;366:1315-23.
13. Arnedo M, Taffé P, Sahli R, et al. Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy. Pharmacogenet Genomics. 2007;17:755-64.
14. Colhoun H, McKeigue P, Davey S. Problems of reporting genetic associations with complex outcomes. Lancet. 2003;361:865-72.
15. Freimer N, Sabatti C. Guidelines for association studies in Human Molecular Genetics. Hum Mol Genet. 2005;14:2481-3.
16. Bozzette S, Ake C, Tam H, et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl Med. 2003;348:702-10.
17. Mary-Krause M, Cotte L, Simon A, et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS. 2003;17:2479-86.
18. Friis-Moller N, Sabin C, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993-2003.
19. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48-62. (Pubitemid 40075680)
20. Friis-Moller N, Reiss P, Sabin C. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723-35.
21. Executive summary of the third report of the National Cholesterol Education Program (NECP). Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
22. Guardiola M, Ferré R, Salazar J, et al. Protease inhibitor -associated dyslipidemia in HIV-infected patients is strongly influenced by the APOA5-1131T>C gene variation. Clin Chem. 2006;52:1914-9.
23. Fauvel J, Bonnet E, Ruidavets J, et al. An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients. AIDS. 2001;15:2397-406.
24. Tarr P, Taffe P, Bleiber G, et al. Modeling the influence of APOC3, APOE and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. J Infect Dis. 2005;191:1419-26.
25. Foulkes A, Whol D, Frank I, et al. Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy. PLoS Med. 2006;3:e52.
26. Miserez A, Muller P, Barella L, et al. A single-nucleotide polymorphism in the sterol-regulatory element-binding protein 1c gene is predictive of HIV-related hyperlipoproteinaemia. AIDS. 2001;15:2045-9.
27. Schaap F, Rensen P, Voshol P, et al. APOAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J Biol Chem. 2004;279:27941-7.
28. Li W, Dammerman M, Smith J, et al. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest. 1995;96:2601-5.
29. Mahley R, Rall S. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet. 2000;1:507-37.
30. Behrens G, Schmidt H, Stoll M, et al. ApoE genotype and protease-inhibitor-associated hyperlipidaemia. Lancet. 1999;354:76.
31. Lister R, Youle M, Nair D, et al. Latent dysbetalipoproteinaemia precipitated by HIV-protease-inhibitors. Lancet. 1999;353:1678.
32. Caron M, Auclair M, Vigouroux C, et al. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes. 2001;50:1378-88.
33. Yang A, King M, Han L, et al. Lack of correlation between SREBP1 genotype and hyperlipidemia in individuals treated with highly active antiretroviral therapy. AIDS. 2003;17:2142-3.
34. Carr A, Emery S, Law M, et al. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet. 2003;361:726-35.
35. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-8.
36. Lo J, Mulligan K, Tai V, et al. "Buffalo hump" in men with HIV-1 infection. Lancet. 1998;351:867-70.
37. Miller K, Jones E, Yanovski J, et al. Visceral abdominal-fat accumulation associated with the use of indinavir. Lancet. 1998;351:871-5.
38. Martínez E, Mocroft A, Garcia-Viejo M, et al. Risk of lipodystrophy in HIV-1 infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 2001;357:592-8.
39. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS. 1999;13:1657-67.
40. Mallal S, John M, Moore C, et al. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS. 2000;14:1309-16.
41. Joly V, Flandre P, Meiffredy V, et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS. 2002;16:2447-54.
42. Mallon P, Miller J, Cooper D, et al. Prospective evaluation on the effects of antiretroviral therapy on body composition in HIV-1 infected men starting therapy. AIDS. 2003;17:971-9.
43. Nolan D, Hammond E, Martin A, et al. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS. 2003;17:1329-38.
44. Miro O, Lopez S, Martínez E, et al. Mitochondrial effects of HIV infection on the peripheral blood mononuclear cells of HIV-infected patients who were never treated with antiretrovirals. Clin Infect Dis. 2004;39:710-6.
45. Zaera M, Miro O, Pedrol E, et al. Mitochondrial involvement in antiretroviral therapy-related lipodystrophy. AIDS. 2001;15:1643-51.
46. Shikuma C, Hu N, Milne C, et al. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS. 2001;15:1801-9.
47. Walker U, Bickel M, Lutke Volksbeck S, et al. Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. J Acquir Immune Defic Syndr. 2002;29:117-21.
48. Martin A, Hammond E, Nolan D, et al. Accumulation of mitochondrial mutations in human immunodeficiency virus-infected patients treated with nucleoside-analogue reverse-transcriptase inhibitors. Am J Hum Genet. 2003;72:549-60.
49. Garg A. Acquired and inherited lipodystrophies. N Engl J Med. 2004;350:1220-34.
50. Dunnigan M, Cochrane M, Kelly A, Scott J. Familial lipoatrophic diabetes with dominant transmission: a new syndrome. Q J Med. 1974;43:33-48.
51. Garg A, Peshock R, Fleckenstein JL. Adipose tissue distribution pattern in patients with familial partial lipodystrophy (Dunnigan variety). J Clin Endocrinol Metab. 1999;84:170-4.
52. Shackleton S, Lloyd D, Jackson S, et al. LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat Genet. 2000;24:153-6.
53. Lloyd D, Trembath R, Shackleton S. A novel interaction between lamin A and SREBP1: implications for partial lipodystrophy and other laminopathies. Hum Mol Genet. 2002;11:769-77.
54. Caron M, Auclair M, Sterlingot H, et al. Some HIV protease inhibitors alter lamin A/C maduration and stability, SREBP-1 nuclear localization and adipocyte differentiation. AIDS. 2003;17:2437-44.
55. Domingo P, Baiget M, Arroyo J, et al. Absence of mutations in exon 8 of the gene in combination antiretroviral therapy-associated partial lipodystrophy. J Acquir Immune Defic Syndr. 2002;30:457-8.
56. Ledru E, Christeff N, Patey O, et al. Alteration of tumor necrosis factor-alpha T-cell homeostasis following potent antiretroviral therapy: contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome. Blood. 2000;95:3191-8.
57. Johnson J, Albu J, Engelson E, et al. Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy. Am J Physiol Endocrinol Metab. 2004;286:E261-71.
58. Maher B, Alfirevic A, Vilar F, et al. TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy. AIDS. 2002;16:2013-8.
59. Nolan D, Moore C, Castley A, et al. Tumour necrosis factor-alpha gene -238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy. AIDS. 2003;17:121-3.
60. Asensi V, Rego C, Montes A, et al. IL-1b (+3954C/T) polymorphism could protect HIV-infected patients on HAART against the lipodystrophic syndrome. Gen Med. 2008;10:215-23.
61. Saumoy M, López-Dupla M, Broch M, et al. A study of the IL-6 system in HIV-1-infected patients with combination antiretroviral therapy-related fat redistribution syndromes. AIDS. 2008;22:893-6.
62. Saumoy M, Veloso S, Alonso-Villaverde C, et al. PPARgamma Pro12Ala Polymorphism in HIV-1-infected Patients with HAART-related Lipodystrophy. Curr HIV Res. 2009;7:533-40.
63. Zanone Poma B, Riva A, Nasi M, et al. Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy. AIDS. 2008;22:1769-78.
64. Ranade K, Geese W, Noor M, et al. Genetic analysis implicates resistin in HIV lipodystrophy. AIDS. 2008;22:1561-8.
65. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-26.
66. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet. 1997;350:430-6.
67. Coll B, Alonso-Villaverde C, Parra S, et al. The stromal derived factor-1 mutated allele (SDF1-3'A) is associated with a lower incidence of atherosclerosis in HIV-infected patients. AIDS. 2005;19:1877-83.
68. Coll B, Parra S, Alonso-Villaverde C, et al. HIV-infected patients with lipodystrophy have higher rates of carotid atherosclerosis: the role of monocyte chemoattractant protein-1. Cytokine. 2006;34:51-5.
69. Alonso Villaverde C, Coll B, Parra S, et al. Atherosclerosis in patients infected with HIV is influenced by a mutant monocyte chemoattractant protein-1 allele. Circulation. 2004;110:2204-9.
70. Abi-Younes S, Sauty A, Mach F, et al. The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques. Circ Res. 2000;86:131-8.
71. Simmons G, Reeves J, Hibbitts S, et al. Co-receptor use by HIV and inhibition of HIV infection by chemokine receptor ligands. Immunol Rev. 2000;177:112-26.
72. Soriano A, Martínez C, Garcia F, et al. Plasma stromal cell-derived factor (SDF)-1 levels, SDF1-3'A genotype, and expression of CXCR4 on T lymphocytes: their impact on resistance to human immunodeficiency virus type 1 infection and its progression. J Infect Dis. 2002;186:922-31.
73. Gear A, Camerini D. Platelet chemokines and chemokine receptors: linking hemostasis, inflammation and host defence. Microrcirculation. 2003;10:335-50.
74. Han K, Tangirala R, Green S, et al. Chemokine receptor CCR2 expression and monocyte chemoattractant protein-1-mediated chemotaxis in human monocytes: a regulatory role for plasma LDL. Arterioscler Thromb Vasc Biol. 1998;18:1983-91.
75. Staszewski S, Morales-Ramírez J, Tashima K, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med. 1999;341:1865-73.
76. Marzolini C, Telenti A, Decosterd L, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;15:1193-4.
77. Gutiérrez F, Navarro A, Padilla S, et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis. 2005;41:1648-53.
78. Csajka C, Marzolini C, Fattinger K, et al. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther. 2003;73:20-30.
79. Hasse B, Gunthard H, Bleiber G, Krause M. Efavirenz intoxication due to slow hepatic metabolism. Clin Infect Dis. 2005;40:e22-3.
80. Lowenhaupt E, Matson K, Qureishi B, Saitoh A, Pugatch D. Psycosis in a 12-year-old HIV-positive girl with an increased serum concentration of efavirenz. Clin Infect Dis. 2007;45:e128-30.
81. Stahle L, Moberg L, Svensson J, Sonnerborg A. Efavirenz plasma concentrations in HIV-infected patients:inter-and intraindividual variability and clinical effects. Ther Drug Monit. 2004;26:267-70.
82. Ward B, Gorski J, Jones D, Hall S, Flockhart D, Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther. 2003;306:287-300.
83. Klein K, Lang T, Saussele T, et al. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet. Genomics. 2005;15:861-73.
84. Lang T, Klein K, Fischer J, et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics. 2001;11:399-415.
85. Haas D, Ribaudo H, Kim R, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Group study. AIDS. 2004;18:2391-400.
86. Tsuchiya K, Gatanaga H, Tachikawa N, et al. Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun. 2004;319:1322-6.
87. Rodriguez-Nóvoa S, Barreiro P, Rendón A, Jiménez-Nacher I, Gonzalez-Lahoz J, Soriano V. Influence of 516 G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis. 2005;40:1358-61.
88. Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics. 2005;15:1-5.
89. Haas D, Smeaton L, Shafer R, et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis. 2005;192:1931-42.
90. Ribaudo H, Haas D, Tierney C, et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group study. Clin Infect Dis. 2006;42:401-7.
91. Wang J, Sonnerborg A, Rane A, et al. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics. 2006;16:191-8.
92. Rotger M, Tegude H, Colombo S, et al. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther. 2007;81:557-66.
93. Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-infected individuals with allelic variants of the multidrug resistant transporter 1: a pharmacogenetics study. Lancet. 2002;359:30-6.
94. Di Iulio J, Fayet A, Arab-Alameddine M, et al. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet Genomics. 2009;19:300-9.
95. Arab-Alameddine M, Di Iulio J, Buclin T, et al. Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Clin Pharmacol Ther. 2009;85:485-94.
96. Motsinger A, Ritchie M, Shafer R, et al. Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study. Pharmacogenet Genomics. 2006;16:837-45.
97. Gatanaga H, Hayashida T, Tsuchiya K, et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P4502B6 *6 and *26. Clin Infect Dis. 2007;45:1230-7.
98. Dieterich D, Robinson P, Love J, Stern J. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin Infect Dis. 2004;38(Suppl 2):S80-9.
99. Stern J, Robinson P, Love J, Lanes S, Imperiale M, Mayers D. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr. 2003;34(Suppl 1):S21-33.
100. Patel S, Johnson S, Belknap S, Chan J, Sha B, Bennett C. Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV infected individuals. J Acquir Immune Defic Syndr. 2004;35:120-5.
101. Martin M, Nolan D, James I, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DBR1*0101 and abrogated by low CD4 T-cell counts. AIDS. 2005;5:97-9.
102. Littera R, Carcassi C, Masala A, et al. HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS. 2006;20:1621-6.
103. Gatanaga H, Yazaki H, Tanuma J, et al. HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS. 2007;21:264-5.
104. Stormer E, von Moltke L, Perloff M, Greenblatt D. Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharm Res. 2002;19:1038-45.
105. Almond L, Edirisinghe D, Dalton M, Bonington A, Back D, Khoo S. Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals. Clin Pharmacol Ther. 2005;78:132-42.
106. Ritchie M, Haas D, Motsinger A, et al. Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse transcriptase inhibitor hepatotoxicity. Clin Infect Dis. 2006;43:779-82.
107. Haas D, Barlett J, Andersen J, et al. Pharmacogenetics of nevirapine associated hepatotoxicity: an adult AIDS Clinical Trials Group collaboration. Clin Infect Dis. 2006;43:783-6.
108. Ciccacci C, Borgiani P, Ceffa S, et al. Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique. Pharmacogenomics. 2010;11:23-31.
109. Plosker G, Noble S. Indinavir: a review of its use in the management of HIV infection. Drugs. 1999;58:1165-203.
110. Busti A, Hall R, Margolis D. Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2004;24:1732-47.
111. Zucker S, Qin X, Rouster S, et al. Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci USA. 2001;98:12671-6.
112. Huang C, Huang M, Lin M, Yang S, Teng H, Tang K. Genetic factors related to unconjugated hyperbilirubinemia amongst adults. Pharmacogenet Genomics. 2005;15:43-50.
113. Rodríguez-Nóvoa S, Martín-Carbonero L, Barreiro P, et al. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS. 2007;21:41-6.
114. Boyd MA, Srasuebkul P, Ruxrungtham K, et al. Relationship between hyperbilirubinemia and UDP-glucuronosyltransferase 1A1(UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir. Pharmacogenet Genomics. 2006;16:321-9.
115. Rotger M, Taffé P, Bleiber G, et al. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis. 2005;192:1381-6.
116. Rodríguez Nóvoa S, Barreiro P, Rendón A, et al. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C->T polymorphism at the multidrug resistance gene 1. Clin Infect Dis. 2006;42:291-5.
117. Lewis W, Copeland W, Day B. Mitochondrial DNA depletion, oxidative stress, and mutation: mechanisms of dysfunction from nucleoside reverse transcriptase inhibitors. Lab Invest. 2001;81:777-90.
118. Keswani S, Pardo C, Cherry C, Hoke A, McArthur J. HIV-associated sensory neuropathies. AIDS. 2002;16:2105-17.
119. Browne M, Mayer K, Chafee S, et al. 2′, 3′-didehydro- 3′-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. J Infect Dis. 1993;167:21-9.
120. Kelleher T, Cross A, Dunkle L. Relation of peripheral neuropathy to HIV treatment in four randomized clinical trials including didanosine. Clin Ther. 1999;21:1182-92.
121. Hulgan T, Haas D, Haines J, et al. Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS Clinical Trial Group study. AIDS. 2005;19:1341-9.
122. Canter J, Haas D, Kallianpur A, et al. The mitochondrial pharmacogenomics of haplogroup T: MTND2 (*) LHON4 917G and antiretroviral therapy-associated peripheral neuropathy. Pharmacogenomics J. 2008;8:71-7.
123. Kallianpur A, Hulgan T, Canter J, et al. Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy. AIDS. 2006;20:1503-13.
124. Lactic Acidosis International Study Group. Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy. AIDS. 2007;21:2455-64.
125. Yamanaka H, Gatanaga H, Kosalaraksa P, et al. Novel mutation of human DNA polymerase χ associated with mitochondrial toxicity induced by anti-HIV treatment. J Infect Dis. 2007;195:1419-25.
126. Coca S, Parazella M. Acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci. 2002;324:342-4.
127. Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis. 2003;36:1070-3.
128. Rifkin B, Perazella M. Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure. Am J Med. 2004;117:282-4.
129. Padilla S, Gutiérrez F, Masiá M, Cánovas V, Orozco C. Low frequency of renal function impairment during one-year of therapy with tenofovircontaining regimens in the real-world: a case-control study. AIDS Patient Care STDS. 2005;19:421-4.
130. Saumoy M, Vidal F, Peraire J, et al. Proximal tubular kidney damage and tenofovir: a role for mitochondrial toxicity? AIDS. 2004;18:1741-2.
131. Gallant J, Parish M, Keruly J, Moore R. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis. 2005;40:1194-8.
132. Mocroft A, Kirk O, Gatell J, et al. Chronic renal failure among HIV-1-infected patients. AIDS. 2007;21:1119-27.
133. Nelson M, Katlama C, Montaner J, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS. 2007;21:1273-81.
134. Zimmermann A, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis. 2006;42:283-90.
135. Murphy M, O'Hearn M, Chou S. Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine. Clin Infect Dis. 2003;36:1082-5.
136. Crane H, Kestenbaum B, Harrington R, Kitahata M. Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir. AIDS. 2007;21:1431-9.
137. Masiá M, Gutiérrez F, Padilla S, Ramos J, Pascual J. Didanosine-associated toxicity: a predictable complication of therapy with tenofovir and didanosine? J Acquir Immune Defic Syndr. 2004;35:427-8.
138. Masiá M, Gutiérrez F, Padilla S, Ramos J, Pascual J. Severe toxicity associated with the combination of tenofovir and didanosine: case report and review. Int J STD AIDS. 2005;16:646-8.
139. Vidal F, Domingo J, Guallar J, et al. In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells. Antimicrob Agents Chemother. 2006;50:3824-32.
140. Venhoff N, Setzer B, Melkaoui K, Walker U. Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors. Antivir Ther. 2007;12:1075-85.
141. Cihlar T, Ray A, Laflamme G, et al. Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors. Antivir Ther. 2007;12:267-72.
142. Motohashi H, Sakurai Y, Saito H, et al. Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol. 2002;13:866-74.
143. Miller D. Nucleoside phosphonate interactions with multiple organic anion transporters in renal proximal tubule. J Pharmacol Exp Ther. 2001;299:567-74.
144. Ray A, Cihlar T, Robinson K, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother. 2006;50:3297-304.
145. Izzedine H, Hulton J, Villard E, et al. Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infec Dis. 2006;194:1481-91.
146. Rodriguez-Nóvoa S, Labarga P, Soriano V, et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis. 2009;48:e108-16.
147. Kiser J, Aquilante C, Anderson P, et al. Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients. J Acquir Immune Defic Syndr. 2008;47:298-303.
148. Argiris A, Mathur-Wagh U, Wilets I, Mildvan D. Abnormalities of serum amylase and lipase in HIV-positive patients. Am J Gastroenterol. 1999;94:1248-52.
149. Cappell M, Marks M. Acute pancreatitis in HIV-seronegative patients: a case control study of 44 patients. Am J Med. 1995;98:243-8.
150. Cohn J, Friedman K, Noone P, Knowles M, Silverman L, Jowell P. Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis. N Engl J Med. 1998;339:653-8.
151. Pfützer R, Barmada M, Brunskill A, et al. SPINK1/PSTI polymorphisms act as disease modifiers in familial and idiopathic chronic pancreatitis. Gastroenterology. 2000;119:615-23.
152. Felley C, Morris M, Wonkam A, et al. The role of CFTR and SPINK-1 mutations in pancreatitis disorders in HIV-positive patients: a case-control study. AIDS. 2004;18:1521-7.
153. Hethrerington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther. 2001;23:1603-14.
154. Escaut L, Liotoer J, Albengres E, et al. Abacavir rechallenge has to be avoided in case of hypersensitivity reaction. AIDS. 1999;13:1419-20.
155. Cutrell A, Hernández J, Fleming J, et al. Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir. Ann Pharmacother. 2004;38:2171-2.
156. Easterbrook P, Waters A, Murad S, et al. Epidemiological risk factors for hypersensitivity reactions to abacavir. HIV Med. 2003;4:321-4.
157. th ICAAC San Francisco 2006; [abstract H-1065].
158. Mallal S, Nolan D, Witt C, et al. Association between presence of HLAB* 5701, HLA-DR7 and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;459;727-32.
159. Hethrerington S, Hughes A, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002;359:1121-2.
160. Martin A, Nolan D, Gaudieri S, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 abd haplotypic Hsp70-Hom variant. Proc Natl Acad Sci USA. 2004;101:4180-5.
161. Rauch A, Nolan D, Martin A, McKinnon E, Almeida C, Mallal S. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in Western Australian HIV cohort study. Clin Infect Dis. 2006;43.99-102.
162. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358:568-79.
163. Saag M, Balu R, Phillips E, et al. High sensitivity of human leukocyte antigen-B*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis. 2008;46:1111-8.
164. Goldman M, Faruki H. Abacavir hypersensitivity: a model system for pharmacogenetic test adoption. Genet Med. 2008;10:874-9.
165. Philips E, Mallal S. Successful translation of pharmacogenetics into the clinic: the abacavir example. Mol Diagn Ther. 2009;13:1-9.
166. GESIDA Expert Panel. National AIDS Plan. GESIDA/AIDS National Plan recommendation with respect to antiretroviral treatment in adults infected with HIV (February 2009 update). Enferm Infecc Microbiol Clin. 2009;27:222-35.